These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25311677)

  • 1. Decade in review-urinary incontinence: advances in female urology and voiding dysfunction.
    Clifton MM; Goldman HB
    Nat Rev Urol; 2014 Nov; 11(11):613-4. PubMed ID: 25311677
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary incontinence in women.
    Wood LN; Anger JT
    BMJ; 2014 Sep; 349():g4531. PubMed ID: 25225003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Pro.
    Ginsberg DA
    J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742453
    [No Abstract]   [Full Text] [Related]  

  • 4. OnabotulinumtoxinA is Preferred over Sacral Neuromodulation for Refractory Overactive Bladder: Con.
    Siegel S
    J Urol; 2017 Jan; 197(1):11-13. PubMed ID: 27742452
    [No Abstract]   [Full Text] [Related]  

  • 5. A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients.
    Chang YH; Hsiao PJ; Chi-Ping H; Wu HC; Hsieh PF; Chou EC
    Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32498306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.
    Elser DM
    Postgrad Med; 2012 May; 124(3):42-9. PubMed ID: 22691898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
    Ginsberg DA; Drake MJ; Kaufmann A; Radomski S; Gousse AE; Chermansky CJ; Magyar A; Nicandro JP; Nitti VW;
    J Urol; 2017 Oct; 198(4):897-904. PubMed ID: 28536084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.
    Miotla P; Futyma K; Cartwright R; Bogusiewicz M; Skorupska K; Markut-Miotla E; Rechberger T
    Int Urogynecol J; 2016 Mar; 27(3):393-8. PubMed ID: 26364180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the value of urodynamic studies before stress incontinence surgery?
    Giarenis I; Cardozo L
    BJOG; 2013 Jan; 120(2):130-132. PubMed ID: 23240793
    [No Abstract]   [Full Text] [Related]  

  • 10. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity.
    Joussain C; Phé V; Even A; Chartier-Kastler E; Denys P
    Eur J Phys Rehabil Med; 2017 Dec; 53(6):991-997. PubMed ID: 29072045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evidence-based approach to urodynamic testing.
    Brubaker L
    BJOG; 2013 Jan; 120(2):127-129. PubMed ID: 23240792
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
    Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN
    Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of post-prostatectomy incontinence with male slings in patients with impaired detrusor contractility on urodynamics and/or who perform Valsalva voiding.
    Han JS; Brucker BM; Demirtas A; Fong E; Nitti VW
    J Urol; 2011 Oct; 186(4):1370-5. PubMed ID: 21855941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamics for incontinence after midurethral sling removal.
    Coskun B; Lavelle RS; Alhalabi F; Lemack G; Zimmern PE
    Neurourol Urodyn; 2016 Nov; 35(8):939-943. PubMed ID: 26207847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gynecology: urinary incontinence - mini-review and case reports].
    Scheiner D; Perucchini D; Fink D; Betschart C
    Praxis (Bern 1994); 2012 Apr; 101(9):585-92. PubMed ID: 22535454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical practice. Idiopathic urgency urinary incontinence.
    Nygaard I
    N Engl J Med; 2010 Sep; 363(12):1156-62. PubMed ID: 20843250
    [No Abstract]   [Full Text] [Related]  

  • 18. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of onabotulinum toxin A injection in pediatric patients with non-neurogenic detrusor overactivity.
    Bayrak O; Sadioglu E; Sen H; Dogan K; Erturhan S; Seckiner I
    Neurourol Urodyn; 2017 Nov; 36(8):2078-2082. PubMed ID: 28195356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials.
    Everaert K; Gruenenfelder J; Schulte-Baukloh H; Egerdie RB; Khalaf K; Joshi M; Ni Q; Sussman D
    Int J Urol; 2015 Dec; 22(12):1131-7. PubMed ID: 26391359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.